PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
Information Note
1 of every 22 people living with HIV
was affected by
a humanitarian emergency in 2013
HIV Treatment - Interim Guidance
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment.
Original Research
African Journal of Primary Health Care & Family Medicine
ISSN: (Online) 2071-2936, (Print) 2071-2928
Open Access
Vinay P. Saldanha( UNAIDS Regional Director- Eastern Europe & Central Asia)
Session 1 Wednesday 30/01/2019
30-31 January 2019, Bucharest
Accessed: 29.09.2019
Meeting Report
Bangkok, Thailand 8-11 August 2016
The COVID-19 pandemic is rapidly spreading across the world and including countries affected by other infectious disease epidemics, such as HIV, tuberculosis (TB) and malaria. Over the past three decades, the global HIV response has gained experience in developing effective prevention approaches. Th...is brief seeks to provide a summary for decision makers and health programme implementers in low- and middle-income countries (LMICs) to help them make the best possible choices in preventing the virus responsible for COVID-19.
more
Inter-Agency Task Team on HIV and Young People
Guidance Brief
Accessed: 09.11.2019
SDG target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, waterborne diseases and other communicable diseases.